News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fujitsu America's BioIT Group Announces New Name, Now Known As BioSciences Group


10/19/2005 5:10:41 PM

PHILADELPHIA, American Chemical Society National Meeting, Aug. 24 /PRNewswire-FirstCall/ -- At the American Chemical Society National Meeting in Philadelphia, the BioIT Group, a division of Fujitsu America, Inc., which is a wholly-owned subsidiary of global IT giant Fujitsu Limited , announced that starting today, it would be known as the BioSciences Group.

"The BioSciences Group is not purely an IT organization. Our goal is to make research more effective -- not just to 'sell boxes,'" said Mr. Yasunori Katsumata, Vice President of Fujitsu America and head of the BioSciences Group. "We are a scientific solutions provider leveraging IT to solve problems for experimental scientists. Our objective is to enable researchers to reduce the trial-and-error guesswork of experimentation by introducing sophisticated automation and modeling capabilities."

Dr. Michael J. McManus, Vice President of Fujitsu America's BioSciences Group said, "The solutions offered by the BioSciences Group are designed for use by the experimenters themselves -- not by IT experts -- to increase end-user productivity. We provide integrated hardware and software computational tools that allow researchers to 'experiment by design,' whether through predictive modeling and simulations, automatic ligand docking calculations, or any one of several possible solution pathways."

About Fujitsu America's BioSciences Group

The BioSciences Group, a division of Fujitsu America, Inc., capitalizes on Fujitsu Limited's over 20 years of leadership in creating innovative and reliable solutions for helping experimental scientists overcome the challenges in their laboratory workflow. The BioSciences Group's solutions provide a framework for researchers to make in silico predictions about leads, targets, and interactions; and to validate these hypotheses experimentally.

Fujitsu America's BioSciences Group offerings include the CAChe(TM) suite of life sciences predictive modeling tools, the ActiveSite(TM) module for drug discovery lead-generation, and the BioServer(TM) massively parallel simulation server for genomics-based drug design. For more information, please see: http://www.fai.fujitsu.com/ .

About Fujitsu

Fujitsu is a leading provider of customer-focused IT and communications solutions for the global marketplace. Pace-setting technologies, highly reliable computing and communications platforms, and a worldwide corps of systems and services experts uniquely position Fujitsu to deliver comprehensive solutions that open up infinite possibilities for its customers' success. Headquartered in Tokyo, Fujitsu Limited reported consolidated revenues of 4.7 trillion yen (US$45 billion) for the fiscal year ended March 31, 2004. For more information, please see: http://www.fujitsu.com/ .

Fujitsu America's BioSciences Group

CONTACT: Joshua Nathan, Marketing Communications Manager of BioSciencesGroup, Fujitsu America, Inc., +1-781-326-6330, or jnathan@us.fujitsu.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES